Kaurenoic acid, a natural substance from traditional herbal medicine, alleviates palmitate induced hepatic lipid accumulation via Nrf2 activation

Changwoo Han*

Department of Internal Medicine, Korean Medicine Hospital and School of Korean Medicine, Pusan National University

**Objectives:** This study was done to look into whether Nrf2 take some role in the anti-lipogenic effect of kaurenoic acid in a nonalcoholic fatty liver disease (NAFLD) cellular model.

**Materials and Methods:** We measured the effect of kaurenoic acid on intracellular steatosis and Nrf2 activation. Next, the effect of kaurenoic acid on SREBP-1c and some lipogenic genes in palmitate treated HepG2 cells with or without Nrf2 silencing.

**Results:** The increased SREBP-1c expression was significantly decreased by concomitant kaurenoic acid treatment in non-targeting negative control siRNA transfected HepG2 cells. However, kaurenoic acid did not significantly inhibited increased SREBP-1c level in Nrf2 specific siRNA transfected HepG2 cells.

**Conclusions:** Kaurenoic acid has a potential to activate Nrf2, which may suppress SREBP-1c mediated intracellular steatosis in HepG2 cells.

**Key Words:** kaurenoic acid, non-alcoholic fatty liver disease, Nrf2

---

**Introduction**

Nonalcoholic fatty liver disease (NAFLD) means hepatic steatosis without secondary causes of hepatic fat accumulation. It can be just steatosis (nonalcoholic fatty liver) or steatosis with inflammation (nonalcoholic steatohepatitis). The overall global prevalence of NAFLD is about 25.24% and the estimated prevalence of nonalcoholic steatohepatitis ranges 1.5 - 6.45%.

Over the past decade, nuclear erythroid 2-related factor 2 (Nrf2) has arisen as an important transcription factor contributing diverse cytoprotective responses. Nrf2 regulates a variety of detoxification proteins, antioxidant enzymes, and efflux transporters, and it is involved in various cellular functions like inflammation, proliferation, and lipid metabolism. Furthermore, due to its hepatoprotective potential, Nrf2 has recently been considered as a target for new therapeutic approaches to treat liver diseases, including NAFLD.

Kaurenoic acid is a natural substance, which
can be found in several plants, including *Aralia continentalis* which is a medicinal herb named 'dokhwal' in traditional Korean medicine\(^5\). In previous studies, it has been confirmed that kaurenoic acid alleviates the intracellular lipid accumulation in HepG2 cells\(^7\) and activates Nrf2 in RAW 264.7 cells\(^8\).

Here in this study, to further explore the mechanism of the anti-steatosis effect of kaurenoic acid, the relationship between its Nrf2 activating potential and pharmaceutical efficacy was investigated in an experimental NAFLD cellular model.

### Materials and Methods

1. **Materials**

Kaurenoic acid (Kaur-16-en-18-oic acid), palmitate, Nile Red, and sulforaphane were products from Sigma-Aldrich Co. (St. Louis, MO, USA). Nrf2 antibody, SREBP-1 antibody, lamin A/C antibody, and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG were products from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

2. **Cell culture**

HepG2 cells were from American Type Culture Collection (Rockville, MD, USA). The cells were cultured in an incubator set at 37 °C with 5 % CO\(_2\) prior to experiment, with Dulbecco's modified Eagle's medium (DMEM) containing 100 µg/ml streptomycin, 100 U/ml penicillin, and 10 % (v/v) heat-inactivated fetal bovine serum.

3. **Steatosis induction and measurement**

For intracellular lipid accumulation, HepG2 cells were incubated in 0.5 mM palmitate containing DMEM for 24h, which incorporates 1% bovine serum albumin. After fixation with 4% paraformaldehyde at room temperature for 15 min, neutral lipid in the cells was stained with 100 ng/ml Nile Red at room temperature for 5 min. Stained lipid was scanned with Olympus FV-1000 confocal laser scanning microscope (Tokyo, Japan), and quantified with ImageJ (Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA).

4. **Western blot analysis**

Total cell extract was prepared by the same way described in previous experiment\(^7\), and nuclear proteins were prepared with NE-PER™ nuclear extraction kit (Thermo Scientific, IL, USA) as per the manufacturer’s instruction. After protein quantification by Bradford assay, each extract with equal amount of protein was put for separation in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were transferred to Polyvinylidene fluoride (PVDF) membrane in electroblotting apparatus and blocked using 5% non-fat milk in Tris-buffered saline (TBS) for 1h at room temperature. The PVDF membrane containing the separated protein blots was incubated with each antibody overnight at 4 °C and thereafter with secondary antibodies for 1 h at room temperature. Chemiluminescence detection kit (SuperSignal® West Femto, Thermo Scientific) was used for visualization of the protein bands.

5. **Semi-quantitative RT–PCR**

RNeasy Mini Kit (Qiagen, Hilden, Germany) was used to prepare total RNA extraction and M-MLV Reverse Transcriptase (Promega, Madison,
WI, USA) for cDNA as per each manufacturer’s instruction. Each cDNA was amplified through PCR using TaqPCRx DNA Polymerase (Invitrogen, Carlsbad, CA, USA). The specific primers are as follows (Table 1). PCR was carried out following the order and conditions: initial denaturation (95°C, 5 min), 22-30 cycles of denaturation (95°C, 40 sec), annealing (57°C, 40 sec), extension (72°C, 50 sec), and a final extension (72°C, 7 min). Each amplicon was put and separated on 1.2% agarose gel in 1×TBE buffer (100 V, 30 min). It was stained with ethidium bromide and scanned under UV light. Using GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) as internal control, relative amount of each gene was calculated through densitometric analysis with software ImageJ (Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA).

| Table 1. The nucleic acid sequences for each primer |
|-----------------------------------------------|
| **Target gene** | **Oligonucleotide sequences** |
|-----------------|-------------------------------|
| NQO-1           | 5'-GCAGTGCTTTCCATCACAGC-3'    |
|                 | 5'-GGAGTCTGACGAGGAGTCA-3'     |
| HO-1            | 5'-GGAACTTTCAGAGAAGCCAG-3'    |
|                 | 5'-GGAAATGTAAGAGGAGGGAGGAG-3' |
| GCLC            | 5'-AAAAGTCCGGTTGCTCTGTC-3'    |
|                 | 5'-TCCGGACATTGTCTCGTA-3'      |
| FAS             | 5'-ACACGGCTTCCATCTGTGTG-3'    |
|                 | 5'-GAGGACATTGTCTCCTGG-3'      |
| SCD-1           | 5'-GCCCTCTCATTGGGAGAGAC-3'    |
|                 | 5'-AAAAGTCCGGTTGCTCTGTC-3'    |
|                 | 5'-TCCGGACATTGTCTCGTA-3'      |
| GAPDH           | 5'-GGAGTCTGACGAGGAGTCA-3'     |

6. Transfection of siRNA

To knockdown Nrf2, HepG2 cells were transfected with Nrf2 specific siRNA (Santa Cruz Biotechnologies, CA, USA) or a non-targeting negative control siRNA (Santa Cruz Biotechnologies, CA, USA) using Lipofectamine TM LTX and PLUS™ Reagent (Invitrogen, Carlsbad, CA, USA) as per the manufacturer’s protocol. Briefly, HepG2 cells were seeded in a 6-well-plate at a density of 2.5 × 10⁴ cells/well with antibiotics-free medium for 12 h before the transfection. 2 μl of the siRNA (10 μM) were mixed with 10 μl Lipofectamine LTX and 0.5μl PLUS reagent in 100 μl serum-free DMEM medium and were incubated at room temperature for 10 minutes to form a complex. After washing cells with PBS, the 100 μl transfection mixtures were added to each well with 900 μl DMEM medium containing 10% FBS at a final concentration of 20 nM siRNA. 24 hours after the transfection, the medium was replaced with fresh 1ml DMEM medium containing 10% FBS.

7. Statistical analysis

The quantified values were statistically analyzed using student’s t-test and one-way analysis of variance (ANOVA) tests with Tukey’s post hoc test. PASW Statistics Data Editor v23 Korean (SPSS Inc, Chicago, IL, USA) was used for analysis, and the mean differences were considered as statistically significant when the P values were less than 0.05.

Results

1. Kaurenoic acid alleviates palmitate-induced intracellular lipid accumulation in HepG2 cells.

In previous study, MTT assay was done in HepG2 cells with various doses of kaurenoic acid to set the safe dose range without cellular toxicity. Viability did not significantly decrease
Kaurenoic acid, a natural substance from traditional herbal medicine, alleviates palmitate induced hepatic lipid accumulation via Nrf2 activation

2. Kaurenoic acid was co-administered with palmitate (0.5 mM) in HepG2 cells. After 24h incubation, Intracellular lipid content was measured as per the protocol. Each value is a relative ratio compared to control (the 1st bar in graph). Bars represent mean±SEM (n=3). The star mark (*) means P<0.05, compared to just palmitate treated cells without KA (the 3rd bar in each graph). Measured absolute values were 5.97±0.57, 5.87±0.56, 13.31±0.75, and 8.59±3.30 respectively, in order from the left bar. Abbreviation: KA, kaurenoic acid.

Fig. 1. The effect of kaurenoic acid on lipid content in HepG2 cells.

Palmitate (0.5 mM) was administered to HepG2 cells to induce intracellular lipid accumulation. Kaurenoic acid (10⁻⁷ M) was co-administered to observe the anti-lipogenic effect of kaurenoic acid. After 24h incubation, the cells were stained, scanned, and quantified the Intracellular lipid content according to the protocol, which was fully described in materials and methods. The palmitate induced lipid accumulation was significantly suppressed by 10⁻⁷ M kaurenoic acid (Figure 1).

Nrf2 protein levels were measured by Western blot analysis. As shown in Figure 2, relative Nrf2 levels were elevated by kaurenoic acid.

Subsequently, the mRNA levels of Nrf2 regulated genes, NQO-1, HO-1, and GCLC were measured by semi-quantitative RT-PCR. As shown in Figure 3, the mRNA expression levels of all three Nrf2 regulated genes were also elevated by kaurenoic acid.

3. Kaurenoic acid suppressed expression of SREBP-1c, but did not in Nrf2-silenced HepG2 cells.

SREBP-1c is a key regulator in intracellular lipogenesis of live tissue⁹. We measured the effect of kaurenoic acid on SREBP-1c expression, a key regulator in intracellular lipogenesis of live tissue, in palmitate treated HepG2 cells with or without Nrf2 silencing. The increased SREBP-1c expression was significantly decreased by

within the range of 10⁻⁵ M for 24 hours (data not shown here)⁹.

Nrf2 protein levels were measured by Western blot analysis. As shown in Figure 2, relative Nrf2 levels were elevated by kaurenoic acid.

Subsequently, the mRNA levels of Nrf2 regulated genes, NQO-1, HO-1, and GCLC were measured by semi-quantitative RT-PCR. As shown in Figure 3, the mRNA expression levels of all three Nrf2 regulated genes were also elevated by kaurenoic acid.

3. kaurenoic acid suppressed expression of SREBP-1c, but did not in Nrf2-silenced HepG2 cells.

SREBP-1c is a key regulator in intracellular lipogenesis of live tissue⁹. We measured the effect of kaurenoic acid on SREBP-1c expression, a key regulator in intracellular lipogenesis of live tissue, in palmitate treated HepG2 cells with or without Nrf2 silencing. The increased SREBP-1c expression was significantly decreased by

within the range of 10⁻⁵ M for 24 hours (data not shown here)⁹.

Kaurenoic acid (10⁻⁷ M) was co-administered with palmitate (0.5 mM) in HepG2 cells. After 24h incubation, Intracellular lipid content was measured as per the protocol. Each value is a relative ratio compared to control (the 1st bar in graph). Bars represent mean±SEM (n=3). The star mark (*) means P<0.05, compared to just palmitate treated cells without KA (the 3rd bar in each graph). Measured absolute values were 5.97±0.57, 5.87±0.56, 13.31±0.75, and 8.59±3.30 respectively, in order from the left bar. Abbreviation: KA, kaurenoic acid.

Fig. 1. The effect of kaurenoic acid on lipid content in HepG2 cells.

Palmitate (0.5 mM) was administered to HepG2 cells to induce intracellular lipid accumulation. Kaurenoic acid (10⁻⁷ M) was co-administered to observe the anti-lipogenic effect of kaurenoic acid. After 24h incubation, the cells were stained, scanned, and quantified the Intracellular lipid content according to the protocol, which was fully described in materials and methods. The palmitate induced lipid accumulation was significantly suppressed by 10⁻⁷ M kaurenoic acid (Figure 1).

Nrf2 protein levels were measured by Western blot analysis. As shown in Figure 2, relative Nrf2 levels were elevated by kaurenoic acid.

Subsequently, the mRNA levels of Nrf2 regulated genes, NQO-1, HO-1, and GCLC were measured by semi-quantitative RT-PCR. As shown in Figure 3, the mRNA expression levels of all three Nrf2 regulated genes were also elevated by kaurenoic acid.

3. kaurenoic acid suppressed expression of SREBP-1c, but did not in Nrf2-silenced HepG2 cells.

SREBP-1c is a key regulator in intracellular lipogenesis of live tissue⁹. We measured the effect of kaurenoic acid on SREBP-1c expression, a key regulator in intracellular lipogenesis of live tissue, in palmitate treated HepG2 cells with or without Nrf2 silencing. The increased SREBP-1c expression was significantly decreased by

http://dx.doi.org/10.13048/jkm.20044
concomitant kaurenoic acid treatment in non-targeting negative control siRNA transfected HepG2 cells (Figure 4A). However, kaurenoic acid did not significantly decreased increased SREBP-1c level in Nrf2 specific siRNA transfected HepG2 cells (Figure 4B).

SREBP-1c induces hepatic steatosis by enhancing a set of enzymes, such as FAS and SCD-1 [10]. When Nrf2 was silenced, kaurenoic acid did not reduced elevated FAS and SCD-1 level in palmitate treated HepG2 cells, too (Figure 5).

Discussion

The pathogenic mechanisms in NAFLD are complicated and comprise a series of sequential steps in which a variety of molecular mediators are involved[13]. It has been recently suggested that Nrf2 activation may alleviate the sequential pathologic processes of NAFLD at several points. First, Nrf2 activation can suppress hepatic lipid accumulation the initial process of the disease[12]. Nrf2 activation may relieve inflammation by repressing NF-κB[13-15] and reduce oxidative stress by increasing SOD and catalase activity[16]. Another point in which Nrf2 activation may prevent NAFLD is hepatic fibrosis by inhibiting TGF-β[17, 18]. In this study, we tried to explore whether Nrf2 plays some role in the anti-lipogenic effect of the kaurenoic acid.

SREBP-1c is a key transcription regulator in lipid metabolism and a set of lipogenic genes, such as ACC, FAS, and SCD-1, are induced by SREBP-1c and increase hepatic steatosis[19]. In previous study, kaurenoic acid reduced the expression of ACC, FAS, and SCD-1 by suppressing SREBP-1c induction[7]. On another experiment, kaurenoic acid activated Nrf2 in RAW 264.7 cells even though not tested in HepG2 cells[8].

So, we hypothesized that Nrf2 activation may be involved in anti-lipogenic effect of kaurenoic acid.

Fig. 3. The effect of kaurenoic acid on expression of Nrf2 dependent genes.

The transcription level of NQO-1 (A), HO-1 (B), and GCLC (C) were measured using semi-quantitative RT-PCR. Each PCR band was measured the optical intensity through densitometric analysis with ImageJ and converted to a relative value over GAPDH. The intensity values were calculated as relative ratios compared to the control (the 1st bar in each graph). Bars represent mean±SEM (n=3). The star mark (*) means *P<0.05, compared to the control. Measured absolute values were 2.46±0.02, 14.44±0.77, 14.60±1.75, and 43.64±1.90 (A); 4.11±0.18, 6.85±0.23, 9.45±0.40, and 10.44±0.56 (B); 3.28±0.20, 7.57±0.33, 7.90±0.45, and 10.57±0.60 (C) respectively, in order from the left bar. Abbreviation: KA, kaurenoic acid.
Kaurenoic acid, a natural substance from traditional herbal medicine, alleviates palmitate induced hepatic lipid accumulation via Nrf2 activation

Fig. 4. The effect of kaurenoic acid on the SREBP–1c expression in Nrf2 siRNA transfected HepG2 cells. Expression levels of SREBP–1c protein were assessed with western blot analysis. The intensity of each band was calculated over the internal control, Lamin A/C. The expression levels of SREBP–1c were expressed as bars on graphs in non–targeting negative control siRNA transfected HepG2 cells (A), and Nrf2 specific siRNA transfected HepG2 cells (B). Each value was converted to a relative ratio compared to control (the 1st bar in each graph). Bars represent mean±SEM (n=3). The star mark (*) means P<0.05, compared to just palmitate treated cells without kaurenoic acid (the 4th bar in each graph). Measured absolute values were 5.26±0.74, 3.86±0.74, 3.84±0.53, 16.94±0.96, 11.22±1.67 and 10.88±1.72 (A); 6.20±0.48, 5.95±0.50, 5.35±0.50, 21.51±3.80, 20.58±3.76 and 17.55±2.24 (B) respectively, in order from the left bar. Abbreviation: KA, kaurenoic acid.

Acid. In the first place, it was confirmed that kaurenoic acid reduced palmitate induced steatosis and activated Nrf2, and Nrf2 regulated cytoprotective genes, NQO-1, HO-1, and GCLC in HepG2 cells. Next, it was verified that kaurenoic acid did not down-regulated SREBP-1c, FAS, and SCD-1 in Nrf2 specific siRNA transfected HepG2 cells, i.e. kaurenoic acid could not reduce lipogenic genes when Nrf2 activation was blocked. Taken together, it seems that kaurenoic acid to relaxes hepatic lipid accumulation by down regulating lipogenic genes through Nrf2 activation. Considering the role of Nrf2 in NAFLD, there could be a possibility that kaurenoic acid also has the potential to subside oxidative stress, inflammation, and even fibrosis.

As of now, there is no proven therapeutic agent though numerous pharmacologic approaches have been examined to treat NAFLD, including insulin sensitizing agents, lipid lowering agents, antioxidants, and etc. As described above, Nrf2 is emerging as a potential target for new therapeutics in NAFLD, and our results show that kaurenoic acid can suppress hepatic lipid accumulation through Nrf2 activation. Thus, we expect that kaurenoic acid can be developed as a potent pharmacologic agent for NAFLD.

Conclusions

We provided evidence that the anti-lipogenic effect of kaurenoic acid may be associated with activation of transcription factor Nrf2, which regulates a variety of cytoprotective response and recently emerged as a promising therapeutic target in preventing and treating several types of liver injury and disease, including NAFLD.

Disclosures

The author does not have a commercial or
other association that might have a conflict of interests.

Acknowledgements

This work was supported by a 2-Year Research Grant of Pusan National University.

References

1. Sourianarayanane A, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2013; 59(1):69-87.

2. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10): 721-8.

3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73-84.

4. Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013;85(6): 705-17.

5. Bataille AM, Manautou JE. Nrf2: a potential target for new therapeutics in liver disease. Clin Pharmacol Ther. 2012;92(3):340-8.

6. Jeong SI, Kim BS, Keum KS, Lee KH, Kang SY, Park BI, et al. Kaurenoic Acid from Aralia continentalis Inhibits Biofilm Formation of Streptococcus mutans. Evid Based Complement Alternat Med. 2013; 2013:160592.

7. Kim YG, Kim YH, Jo YW, Kwun MJ, Han CW. Kaurenoic acid, a Diterpene Derived from Aralia continentalis, Alleviates Lipogenesis in HepG2 Cells. J Korean Med. 2015;36(4):74-9.

8. Choi RJ, Shin EM, Jung HA, Choi JS, Kim YS. Inhibitory effects of kaurenoic acid from Aralia continentalis on LPS-induced
inflammatory response in RAW264.7 macrophages. Phytomedicine. 2011;18(8-9): 677-82.

9. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 2008;21(4): 507-11.

10. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab. 2010;12 Suppl 2:83-92.

11. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002; 277(37):34182-90.

12. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol. 2009;620(1-3):138-44.

13. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who's listening? Antioxid Redox Signal. 2010;13(11): 1649-63.

14. Seldon MP, Silva G, Pejanovic N, Larsen R, Gregoire IP, Filipe J, et al. Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J Immunol. 2007;179(11): 7840-51.

15. Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol. 2008;181(10):6730-7.

16. Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radic Biol Med. 2006;40(2): 341-7.

17. Oh CJ, Kim JY, Min AK, Park KG, Harris RA, Kim HJ, et al. Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. Free Radic Biol Med. 2012;52(3):671-82.

18. Choi HK, Pokharel YR, Lim SC, Han HK, Ryu CS, Kim SK, et al. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. Toxicol Appl Pharmacol. 2009;240(3):377-84.

19. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147-52.

20. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-22.

ORCID

Changwoo Han https://orcid.org/0000-0001-9596-1151

http://dx.doi.org/10.13048/jkm.20044 71